1 No reference.

2 Research on the Menopause in the 1990s Report of a WHO Scientific Group. World Health Organisation, WHO Technical Report Series No. 866, 1996.

3 Spencer CP, Cooper AJ, Whitehead MI. Management of abnormal bleeding in women receiving hormone replacement therapy. BMJ 1997; 315: 37-42.

4 Ettinger B, Li DK, Klein R. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Fertil Steril 1998;69:865-9.

5 Ferrazzi E, Torri V, Trio D, Zannoni E, Filiberto S, Dordoni D. Sonographic endometrial thickness: a useful test to predict atrophy in patients with postmenopausal bleeding. An Italian multicenter study. Ultrasound Obstet Gynecol 1996; 7: 315-21. [section 2.1] [section 2.1.4]

6 Gredmark T, Kvint S, Havel G, Mattsson LA. Histopathological findings in women with postmenopausal bleeding. Br J Obstet Gynaecol 1995; 102: 133-6. [section 2.1] [section 2.1.1] [section 5]

7 Lidor A, Ismajovich B, Confino E, David MP. Histopathological findings in 226 women with post-menopausal uterine bleeding. Acta Obstet Gynecol Scand 1986; 65: 41-3.

8 Harris V, Sandridge AL, Black RJ, Brewster DH, Gould A. Cancer registration statistics Scotland 1986-1995 Edinburgh: ISD Scotland Publications; 1998. [cited 14 May 2002]. Available from url:http://www.show.scot.nhs.uk/isd/Scottish_Health_Statistics/subject/cancerregistra/

9 Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131-7.

10 Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software.

11 Barrett-Connor E. Hormone replacement therapy. BMJ 1998; 317: 457-61.

12 Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in post menopausal women taking continuous combined or sequential regimens of comjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynaecol 1994; 83: 686-92.

13 Nagele F, O'Connor H, Baskett TF, Davies A, Mohammed H, Magos AL. Hysteroscopy in women with abnormal uterine bleeding on hormone replacement therapy: a comparison with postmenopausal bleeding. Fertil Steril 1996; 65:1145-50. [section 2] [section 4]

14 Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995; 87: 645-51.

15 Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88.

16 Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117-20.

17 Curtis RE, Boice JD Jr, Shriner DA, Hankey BF, Fraumeni JF Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996; 88: 832-4.

18 Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999 Oct 6; 91:1654-62.

19 van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448-52.

20 Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Lancet 2000; 356: 881-7.

21 Tepper R, Beyth Y, Altaras MM, Zalel Y, Shapira J, Cordoba M, Cohen I. Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol 1997; 64: 386-91.

22 Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999; 17: 2050-4.

23 Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997; 6: 105-10.

24 Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214-8.

25 Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, et al. Cancer risk in families with herediary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110: 1020-7.

26 Feldman S, Cook EF, Harlow BL, Berkowitz RS. Predicting endometrial cancer among older women who present with abnormal vaginal bleeding. Gynecol Oncol 1995; 56: 376-81.

27 Department of Health. Referral guidelines for suspected cancer. London: The Department; 2000. [cited on 14 May 2002]. Available from url: http://www.doh.gov.uk/cancer/referral.htm

28 Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998; 280: 1510-7. [section 3] [section 4.3] [section 4.3.1] [section 5]

29 Chien PFW, Voit D, Clark TJ, Khan KS, Gupta JKl. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: A meta-analysis. Acta Obstet Gynecol Scand. In press 2002. [section 4.3] [section 4.3.1] [section 5]

30 Wolman I, Amster R, Hartoov J, Gull I, Kupfermintz M, Lessing JB, et al. Reproducibility of transvaginal ultrasonographic measurements of endometrial thickness in patients with postmenopausal bleeding. Gynecol Obstet Invest. 1998; 46: 191-4. [section 4] [section 5]

31 Dijkhuizen FP, Brolmann HA, Potters AE, Bongers MY, Heintz AP. The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities. Obstet Gynecol. 1996; 87: 345-9. [section 4.3.1] [section 4.3.5]

32 Guner H, Tiras MB, Karabacak O, Sarikaya H, Erdem M, Yildirim M. Endometrial assessment by vaginal ultrasonography might reduce endometrial sampling in patients with postmenopausal bleeding: a prospective study. Aust NZ J Obstet Gynaecol 1996; 36: 175-8. [section 4.3] [section 4.6]

33 Garuti G, Sambruni I, Cellani F, Garzia D, Alleva P, Luerti M. Hysteroscopy and transvaginal ultrasonography in postmenopausal women with uterine bleeding. Int J Gynaecol Obstet 1999; 65: 25-33. [section 4.3.1] [section 4.3.5]

34 Wolman I, Sagi J, Ginat S, Jaffa AJ, Hartoov J, Jedwab G. The sensitivity and specificity of vaginal sonography in detecting endometrial abnormalities in women with postmenopausal bleeding. J Clin Ultrasound. 1996; 24: 79-82.

35 Granberg S, Ylostalo P, Wikland M, Karlsson B. Endometrial sonographic and histologic features in women with and without hormonal replacement therapy suffering from postmenopausal bleeding. Maturitas 1997; 27: 35-40.

36 Mendelson EB, Bohm-Velez M, Joseph N, Neiman HL. Gynecologic imaging: comparison of transabdominal and transvaginal sonography. Radiology 1988;166:321-4.

37 Tsuda H, Kawabata M, Umesaki N, Kawabata K, Ogita S. Endometrial assessment by transabdominal ultrasonography in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 1993; 52: 201-4. [section 4.3.2] [section 4.6]

38 O'Connell LP, Fries MH, Zeringue E, Brehm W. Triage of abnormal postmenopausal bleeding: a comparison of endometrial biopsy and transvaginal sonohysterography versus fractional curettage with hysteroscopy. Am J Obstet Gynecol 1998; 178: 956-61. [section 4.3.1] [section 4.3.3]

39 Sladkevicius P, Valentin L, Marsal K. Endometrial thickness and Doppler velocimetry of the uterine arteries as discriminators of endometrial status in women with postmenopausal bleeding: a comparative study. Am J Obstet Gynecol 1994; 171: 722-8. [section 4.3.3] [section 4.6]

40 Gruboeck K, Jurkovic D, Lawton F, Savvas M, Tailor A, Campbell S. The diagnostic value of endometrial thickness and volume measurements by three-dimensional ultrasound in patients with postmenopausal bleeding. Ultrasound Obstet Gynecol 1996; 8: 272-6.

41 Conoscenti G, Meir YJ, Fischer-Tamaro L, Maieron A, Natale R, D'Ottavio G, et al. Endometrial assessment by transvaginal sonography and histological findings after D & C in women with postmenopausal bleeding. Ultrasound Obstet Gynecol 1995; 6: 108-15.

42 Weber G, Merz E, Bahlmann F, Rosch B. Evaluation of different transvaginal sonographic diagnostic parameters in women with postmenopausal bleeding. Ultrasound Obstet Gynecol 1998; 12: 265-70.

43 Grimes DA. Diagnostic dilation and curettage: a reappraisal. Am J Obstet Gynecol 1982; 142: 1-6. [section 4.3.1] [section 4.3.4] [section 4.6]

44 Stock RJ, Kanbour A. Prehysterectomy curettage. Obstet Gynecol 1975; 45: 537-41.

45 Haller H, Matecjcic N, Rukavina B, Krasevic M, Rupcic S, Mozetic D. Transvaginal sonography and hysteroscopy in women with postmenopausal bleeding. Int J Gynaecol Obstet 1996; 54: 155-9. [section 4.3.5] [section 4.6]

46 Gordon SJ, Westgate J. The incidence and management of failed Pipelle sampling in a general outpatient clinic. Aust N Z J Obstet Gynaecol 1999; 39: 115-8.

47 Tahir MM, Bigrigg MA, Browning JJ, Brookes ST, Smith PA. A randomised controlled trial comparing transvaginal ultrasound, outpatient hysteroscopy and endometrial biopsy with inpatient hysteroscopy and curettage. Br J Obstet Gynaecol1999; 106: 1259-64. [section 4.3.5] [section 4.3.6]

48 Etherington IJ, Harrison KR, Read MD. A comparison of outpatient endometrial sampling with hysteroscopy, curettage and cystoscopy in the evaluation of postmenopausal bleeding. J Obstet Gynaecol 1995; 15: 259-62.

49 Giusa-Chiferi MG, Goncalves WJ, Baracat EC, de Albuquerque Neto LC, Bortoletto CC, de Lima GR. Transvaginal ultrasound, uterine biopsy and hysteroscopy for post menopausal bleeding. Int J Gynaecol Obstet 1996; 55: 39-44.

50 Van den Bosch T, Vandendael A, Van Schoubroeck D, Wranz PA, Lombard CJ. Combining vaginal ultrasonography and office endometrial sampling in the diagnosis of endometrial disease in the diagnosis of endometrial disease in postmenopausal women. Obstet Gynecol 1995; 85: 349-52.

51 Shaker AG, Anderson M, Kitchener HC, Miller ID. An out-patient approach to the management of post-menopausal bleeding. Br J Obstet Gynaecol 1991; 98: 488-90.

52 Kremer C, Duffy S, Moroney M. Patient satisfaction with outpatient hysteroscopy versus day case hysteroscopy: randomised controlled trial. BMJ 2000; 320: 279-82.

53 Franchi M, Ghezzi F, Donadello N, Zanaboni F, Beretta P, Bolis P. Endometrial thickness in tamoxifen-treated patients: an independent predictor of endometrial disease. Obstet Gynecol 1999; 93: 1004-8.

54 Tesoro MR, Borgida AF, MacLaurin NA, Asuncion CM. Transvaginal endometrial sonography in postmenopausal women taking tamoxifen. Obstet Gynecol 999; 93: 363-6.

55 Timmerman D, Deprest J, Bourne T, Van den Berghe I, Collins WP, Vergote I. A randomized trial on the use of ultrasonography or office hysterography for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. Am J Obstet Gynecol 1998; 179: 62-70.

56 Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Pacini P, Muraca MG, et al. Risk of endometrial cancer in breast cancer patients under long-term adjuvant treatment with tamoxifen. Tumori 1998; 84: 21-3.

57 Tepper R, Beyth Y, Altaras MM, Zalel Y, Shapira J, Cordoba M, et al. Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol 997; 64: 386-91.

58 Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999; 17: 2050-4.

59 Berliere M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol
1998; 91: 40-4.

60 Gerber B, Krause A, Muller H, Reimer T, Kulz T, Makovitzky J, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000; 18: 3464-70.

61 Barakat RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, Hudis C, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 2000; 18: 3459-63.

62 Bornstein J, Auslender R, Pascal B, Gutterman E, Isakov D, Abramovici H. Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. Reprod Med 1994; 39: 674-8.

63 Mourits MJ, Van der Zee AG, Willemse PH, Ten Hoor KA, Hollema H, De Vries EG. Discrepancy between ultrasonography and hysterography and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol 1999; 73: 21-6.

64 Jaeschke R, Guyatt GH, Sackett DL. Users' guide to the medical literature. II. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group JAMA 1994;271:703-7.

65 Bakour SH, Khan KS, Gupta JK. Transvaginal ultrasonography and endometrial histology in peri- and postmenopausal women on hormone replacement therapy. Br J Obstet Gynaecol 2000; 107: 295-8.

66 Gambrell RD Jr, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980; 55: 732-8.

67 Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298: 147-51.

68 Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, Bossuyt PM. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:1061-6.